63 studies found for:    nivolumab | Open Studies
Show Display Options
Rank Status Study
1 Not yet recruiting Nivolumab With Ibrutinib for Relapsed, Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Leukemia;   Chronic Lymphocytic Leukemia
Interventions: Drug: Nivolumab;   Drug: Ibrutinib
2 Recruiting PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
Conditions: Advanced Melanoma;   Metastatic Melanoma
Interventions: Biological: Nivolumab;   Drug: Ipilimumab
3 Recruiting A Study of Nivolumab (BMS-936558) in Combination With 5-azacytidine (Vidaza) for the Treatment of Patients With Refractory/ Relapsed Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Drug: 5-azacytidine;   Drug: Nivolumab;   Behavioral: Phone Call
4 Recruiting Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Conditions: Breast Neoplasms;   Pancreatic Neoplasms
Interventions: Drug: nab-Paclitaxel;   Drug: Nivolumab;   Drug: Gemcitabine;   Drug: Carboplatin
5 Recruiting Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma
Conditions: Melanoma;   Uveal Melanoma
Interventions: Drug: Nivolumab;   Drug: Ipilimumab
6 Recruiting Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
Conditions: Childhood Solid Neoplasm;   Recurrent Childhood Hodgkin Lymphoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Childhood Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacological Study
7 Recruiting Safety Study in Nivolumab Alone and in Combination With Ipilimumab or Lirilumab in Lymphoma and Multiple Myeloma
Conditions: Non-Hodgkin's Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Lirilumab
8 Recruiting Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Condition: Non-small Cell Lung Cancer
Interventions: Biological: Nivolumab;   Drug: Gemcitabine;   Drug: Cisplatin;   Drug: Pemetrexed;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Bevacizumab;   Drug: Erlotinib;   Biological: Ipilimumab
9 Recruiting A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis
Condition: Brain Metastases
Interventions: Drug: Fotemustine;   Drug: Fotemustine and Ipilimumab;   Drug: Ipilimumab and nivolumab
10 Not yet recruiting Nivolumab and Ipilimumab in Treating Patients With Advanced HIV Associated Solid Tumors
Conditions: Adult Solid Neoplasm;   Anal Carcinoma;   HIV Infection;   Kaposi Sarcoma;   Lung Carcinoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
11 Not yet recruiting Nivolumab and HPV-16 Vaccination in Patients With HPV-16 Positive Incurable Solid Tumors
Condition: Solid Tumors
Interventions: Biological: ISA 101;   Drug: Nivolumab
12 Recruiting A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)
Condition: Renal Cell Carcinoma
Intervention: Drug: nivolumab
13 Not yet recruiting Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
Conditions: Nasopharyngeal Nonkeratinizing Carcinoma;   Recurrent Nasopharyngeal Undifferentiated Carcinoma;   Stage III Nasopharyngeal Undifferentiated Carcinoma;   Stage IV Nasopharyngeal Undifferentiated Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
14 Recruiting Nivolumab vs Nivolumab + Bevacizumab vs Nivolumab + Ipilimumab in Metastatic Renal Cell Carcinoma (mRCC)
Condition: Kidney Cancer
Interventions: Drug: Nivolumab;   Drug: Bevacizumab;   Drug: Ipilimumab
15 Not yet recruiting Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
Conditions: Adult Solid Neoplasm;   Breast Adenocarcinoma;   HER2/Neu Negative;   Invasive Breast Carcinoma;   Recurrent Breast Carcinoma;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Entinostat;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Pharmacological Study
16 Recruiting Study of the Safety and Tolerability of Urelumab Administered in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkins Lymphoma
Conditions: Advanced Solid Tumors;   Advanced B-cell NHL
Interventions: Biological: Urelumab;   Biological: Nivolumab
17 Not yet recruiting Nivolumab in Eliminating Minimal Residual Disease and Preventing Relapse in Patients With Acute Myeloid Leukemia in Remission After Chemotherapy
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1;   Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL;   Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA;   Alkylating Agent-Related Acute Myeloid Leukemia
Interventions: Other: Clinical Observation;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
18 Recruiting Study of Nivolumab in Patients With Myelofibrosis
Condition: Myeloproliferative Diseases
Interventions: Drug: Nivolumab;   Behavioral: Questionnaire;   Behavioral: Phone Call
19 Not yet recruiting A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, Hepatocellular Carcinoma, or Glioma
Conditions: Solid Tumor;   Non-Small Cell Lung Cancer Recurrent;   Hepatocellular Carcinoma Recurrent;   Glioma
Interventions: Drug: Galunisertib;   Drug: Nivolumab
20 Not yet recruiting Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma of the Skin;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Biological: Sargramostim

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years